Observational Study of Intra Arterial Therapies for Primary Liver Cancer Evaluating Treatment Responses and Outcomes

What this Trial Is About

Researchers are studying the best conditions for successful treatment outcomes in men and women with primary liver cancer using intra arterial therapy (IAT). This observational study focuses on hepatocellular carcinoma (HCC) and cholangiocarcinoma cancers, aiming to understand how these radiologic procedures that block blood supply to liver tumors affect patients. The study combines both retrospective and prospective data collection at the Radiology department of the IRCCS Azienda Ospedaliera Universitaria Hospital in Bologna. The study includes two phases: a retrospective phase analyzing radiological images from patients who received intra arterial therapy since January 1, 2009, with an expected enrollment of around 2000 participants, and a prospective phase enrolling about 1300 eligible participants over 5 years who will receive intra arterial therapy. Treatments studied include trans-arterial embolization (TAE), transarterial chemoembolization (TACE), transarterial radioembolization (TARE), and drug-eluting beads chemoembolization (DEB-TACE), all performed as part of routine clinical care. Participants will be monitored through clinical and radiological evaluations including CT scans and MRI to assess the type and size of the cancer, treatment response, and possible complications over a follow-up period extending up to 9 years. Researchers will collect data on injury type and size, radiological response, and post-treatment complications from enrollment through the end of treatment. The study aims to identify factors linked to optimal treatment responses and long-term outcomes.

Intra Artherial Therapies in Treatment of Primary Liver Diseases: an Observational Study